Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 3/20 | 0.42 |
| ▸ | GHSR | Q92847 | 6/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22180463 | 0.88 | DRD2 (0.44) | UCHL1GHSRNR1H2NR1H3RXRA | |
| SCHEMBL17674733 | 0.88 | DRD2 (0.44) | UCHL1GHSRNR1H2NR1H3RXRA | |
| SCHEMBL29705854 | 0.86 | UCHL1 (0.39) | UCHL1GHSRNR1I2GPR119DDB1 | |
| SCHEMBL19489600 | 0.86 | UCHL1 (0.39) | UCHL1GHSRNR1I2GPR119DDB1 | |
| SCHEMBL24495434 | 0.85 | UCHL1 (0.43) | UCHL1DDB1CRBNNR1H2DRD2 | |
| SCHEMBL30682966 | 0.85 | UCHL1 (0.43) | UCHL1DDB1CRBNNR1H2DRD2 | |
| SCHEMBL17681742 | 0.84 | UCHL1 (0.55) | UCHL1NR1I2GPR119DDB1CRBN | |
| SCHEMBL7996670 | 0.84 | UCHL1 (0.43) | UCHL1GHSRNR1I2GPR119DDB1 | |
| SCHEMBL17681690 | 0.84 | UCHL1 (0.55) | UCHL1NR1I2GPR119DDB1CRBN | |
| SCHEMBL29608082 | 0.84 | UCHL1 (0.55) | UCHL1NR1I2GPR119DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | UCHL1 261/4885GHSR 2085/4885NR1I2 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.